BioNTech SE
25 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
14
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Particles comprising a shell with RNA (US 11,660,338) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Dec 13, 2026The maintenance fee for Compositions and Methods for Diagnosis and Treatment of Cancer (US 11,673,939) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 3 fees due Jan 7 to 28, 2027 · next Jan 7
- 2 fees due Feb 1 to 6, 2027 · next Feb 1
- 1 fee due Mar 19, 2027The maintenance fee for Human Monoclonal Antibodies to Ganglioside GD2 (US 11,760,809) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 4 fees due Apr 1 to 29, 2027 · next Apr 1
- 3 fees due May 3 to 26, 2027 · next May 3
- 4 fees due Jul 9 to 23, 2027 · next Jul 9
- 5 fees due Sep 3 to 29, 2027 · next Sep 3
- 3 fees due Oct 9 to 26, 2027 · next Oct 9
Recent changes
- 4 of the patents on this record were granted since Aug 20, 2026
- 3 terms have ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,875,424 | Identification of Tumour-Associated Cell Surface Antigens for Diagnosis and Therapy In force · High confidence | In force | High confidence | |
| US 8,178,653 | Recombinant Vaccines and Use Thereof In force · High confidence | In force | High confidence | |
| US 9,090,940 | Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy In force · Medium confidence | In force | Medium confidence | |
| US 11,020,477 | RNA Vaccines In force · Medium confidence | In force | Medium confidence | |
| US 10,253,373 | Identification of Tumor-Associated Markers for Diagnosis and Therapy In force · High confidence | In force | High confidence | |
| US 8,258,258 | Dimeric or multimeric microproteins In force · From the USPTO record | In force | From the USPTO record | |
| US 11,008,550 | Use of RNA for reprogramming somatic cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,446,040 | Substituted imidazoquinolines In force · From the USPTO record | In force | From the USPTO record | |
| US 9,908,880 | Substituted imidazoquinolines In force · From the USPTO record | In force | From the USPTO record | |
| US 8,349,558 | Detection of Individual T-Cell Reaction Patterns Against Tumor-Associated Antigens (TAA) in Tumor Patients as a Basis for the Individual Therapeutic Vaccination of Patients In force · High confidence | In force | High confidence |
Also on record, not counted in the 120: 25 patents in force now held by others · 7 lapsed for an unpaid fee · 21 ended at full term · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
84 pending · 24 abandoned · 15 no status recorded